Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

A2 Milk's push into China bolstered

A2 Milk's push into China bolstered by results of human clinical trial in that country

By Fiona Rotherham

April 19 (BusinessDesk) - Specialty milk marketer A2 Milk has bolstered its push to sell more products in China through a recently completed human clinical trial comparing the gastrointestinal and cognitive effects of consuming milk containing the A1 beta casein with that of the A2 variant on people with self-reported lactose intolerance.

The results of the Chinese study were published this month in the Nutrition Journal and are due to be released at a Beijing press conference late tomorrow by the company.

It’s part of a bid by A2 to get more credible scientific validation of its marketing claims, that have been in contention since the late 1990s, that its products might be better for people intolerant to standard cow milk.

Cows naturally produce more than 200 different proteins with beta-casein comprising about 30 percent or 2.5 grams per glass. The A2 beta-casein was originally in cattle when first domesticated and the A1 beta-casein arose from a later genetic mutation in European cattle.

A2 Milk’s marketing material claims A1’s BCM-7 can trigger inflammation in the body that could “potentially” lead to medical problems such as irritable bowel syndrome, autism and schizophrenia but until now it’s had no hard scientific evidence from human clinical trials to back that up.

The Chinese study of 45 Han Chinese people compared the impact of consuming milk with the A1 beta-casein with that of milk containing only the A2 variant over a three-month period.

It found milk containing the A1 beta-casein worsened gastrointestinal symptoms and slowed cognitive processing speed whereas the milk with A2 beta-casein had no adverse effect.

The study’s authors conclude that “because elimination of the A1 B-casein attenuated these effects, some symptoms of lactose intolerance may stem from inflammation it triggers, and can be avoided by consuming milk containing only the A2 type of beta-casein.”

A second clinical trial is now underway on 600 people in China, including adults and infants.

In New Zealand the government is contributing around $1 million to human clinical trials under the High-Value Nutrition Challenge in partnership with A2, AgResearch and the University of Auckland.

The A1 and A2 beta-caseins are different in structure, and subsequently, the way they are digested. AgResearch scientist Matthew Barnett told a High-Value Nutrition Challenge conference last week that human beta-caseins are more like A2 than the A1 variant.

He said it was important to be able to demonstrate health benefits from A2 Milk to support charging a premium for the product. While the rest of the dairy industry has faced low global prices, A2 Milk has been able to charge more than double the price of standard milk and gained just under 10 percent of the fresh milk market in Australia.

A2's profit for the half-year was up almost 800 percent to $10.1 million on the back of booming demand for its infant formula powder in China and Australia while revenue from China alone rose 680 percent to $8.4 million.

Barnett said despite the success of the Chinese study, the effects of the A1 beta-casein needs to be further demonstrated in other human clinical trials.

He said the double-blind cross-over Auckland studies hope to produce ethically significant evidence on comparisons between the two milks and better understand why that occurs to back up A2 Milk’s health claims. MRI imaging will be used to show changes within a short timeframe as the milk moves through the gut alongside analysis of compounds in patient's breath.

The first trial involving 12 people will begin this year and if the results are positive, a second study of a larger cohort of around 40 people will then be conducted based on what data will best “tell the story”, he said.

A2 Milk is also in the final stages of implementing human clinical trials on the same digestive impact of the milk with a leading US biomedical research centre and in the UK.

(BusinessDesk)

© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 



Consumer NZ: Buy-now, Pay-later Raking In $10m+ In Late Fees Annually

A Consumer NZ survey has found buy-now, pay-later services are costing shoppers more than $10 million a year in late fees. Close to four out of 10 Kiwi consumers use buy-now, pay-later services, such as Afterpay, Laybuy and Zip... More>>

Westpac: Catherine Mcgrath Appointed New Zealand CEO

Westpac Group CEO Peter King and the Westpac New Zealand Board today announced the appointment of Catherine McGrath as Chief Executive Officer, Westpac New Zealand... More>>


Amazon: AWS To Open Data Centres In New Zealand

Today, Amazon Web Services (AWS), announced plans to open an infrastructure region in Aotearoa New Zealand in 2024. The new AWS Asia Pacific (Auckland) Region will consist of three Availability Zones (AZs) and join the existing 81 Availability Zones across 25 geographic AWS Regions at launch... More>>

ALSO:



Statistics: Surge In Imports Results In Record Monthly Trade Deficit
Imports increased $1.8 billion in August 2021 compared with August 2020, resulting in a record monthly trade deficit of $2.1 billion, Stats NZ said today. Exports were little changed, down $42 million. "This is a larger deficit than normal because of higher values for imports.. More>>

Fonterra: Completes reset, announces annual results and long-term growth plan out to 2030

Fonterra Co-operative Group Limited today announced a strong set of results for the 2021 financial year, reflected in a final Farmgate Milk Price of $7.54, normalised earnings per share of 34 cents and a final dividend of 15 cents... More>>


Statistics: GDP rises in the June 2021 quarter

Gross domestic product (GDP) rose by 2.8 percent in the June 2021 quarter, following a 1.4 percent increase in the March 2021 quarter, Stats NZ said today. June 2021 quarter GDP was 4.3 percent higher when compared with the December 2019 quarter... More>>